Screener
4D Molecular Therapeutics FDMT Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $3.78M+25,107% | $3.05M+21,664% | $85.09M+8,508,900% | $90K+2,900% | $15K+200% | ||
| $68.28M+42.4% | $64.98M+59.7% | $57.61M+33.7% | $49.44M+28.5% | $47.95M+50.5% | ||
| $12.52M+8.7% | $11.69M-9.7% | $12.77M-2.0% | $11.84M-6.4% | $11.52M+8.7% | ||
| $80.81M+35.9% | $76.67M+42.9% | $70.38M+25.4% | $61.28M+19.8% | $59.47M+40.1% | ||
| -$77.03M-29.5% | -$73.62M-37.3% | $0+100% | -$61.19M-19.7% | -$59.46M-40.0% | ||
| -2,037.2%+394,336pp | -2,416.1%+380,591pp | 0%+5,611,700pp | -67,983.3%+1,636,417pp | -396,373.3%+452,747pp | ||
| $4.09M-14.8% | $4.86M-14.0% | $4.68M-27.4% | $4.31M-40.9% | $4.8M-36.1% | ||
| -$72.94M-33.4% | -$68.76M-43.3% | —— | -$56.88M-29.7% | -$54.66M-56.4% | ||
| -1,929%+362,458pp | -2,256.6%+340,400pp | —— | -63,195.6%+1,398,238pp | -364,386.7%+334,673pp | ||
| -$1.04-6.1% | -$1.01-17.4% | —— | -$1.01-27.8% | -$0.98-55.6% | ||
| -$75.75M-29.9% | -$72.35M-37.6% | $1.22M+102% | -$59.92M-20.0% | -$58.29M-41.3% | ||
| -2,003.3%+386,597pp | -2,374.5%+373,126pp | 1.4%+5,502,101pp | -66,582.2%+1,598,151pp | -388,600%+436,640pp | ||
| -$77.03M-29.5% | -$73.62M-37.3% | $0+100% | -$61.19M-19.7% | -$59.46M-40.0% |
FAQ
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $92.0M in revenue over the trailing twelve months, up 278712.1% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $253.2M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-4.04.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
